Literature DB >> 22257476

6-Mercaptopurine transport in human lymphocytes: correlation with drug-induced cytotoxicity.

Laurie S Conklin1, Carmen Cuffari, Toshihiko Okazaki, Yinglei Miao, Bahman Saatian, Tian-E Chen, Ming Tse, Steven R Brant, Xuhang Li.   

Abstract

OBJECTIVE: 6-mercaptopurine (6-MP) is efficacious in the treatment of inflammatory bowel disease (IBD). However, about one-third of patients respond poorly to therapy. This study aimed to characterize the inherent differences in 6-MP transport that may cotribute to the differences in treatment responses.
METHODS: Intracellular 6-MP accumulation was assayed in Epstein-Barr virus (EBV)-transformed lymphocytes from IBD patients, using (14) C-radiolabeled 6-MP. Cell proliferation was determined by methyl thiazolyl tetrazolium (MTT) assay. Apoptosis was assayed based on the activation of caspase 3. The expressions of 15 potential 6-MP transporters were evaluated by reverse transcription-polymerase chain reaction (RT-PCR).
RESULTS: Intracellular 6-MP accumulation, varying significantly among patients, was carrier-dependent and partially sodium-dependent. 6-MP cytotoxicity was, at least in part, due to apoptosis and correlated with intracellular drug accumulation. The efflux transporters did not appear to contribute to the variability of intracellular drug accumulation between patients, since none correlated with drug accumulation or cytotoxicity. Rather, differential expression of five influx/uptake transporters might be a key contributor to the difference in the accumulation of and susceptibility to the drug.
CONCLUSIONS: The heterogeneity of the drug transporters may be the reason for the therapeutic sensitivity of 6-MP in IBD patients. As the 6-MP uptake is a carrier-mediated and partially sodium-dependent process, future studies are necessary to evaluate the role of the putative transporters and their correlation with drug sensitivity in patients.
© 2012 The Authors. Journal of Digestive Diseases © 2012 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22257476      PMCID: PMC3758926          DOI: 10.1111/j.1751-2980.2011.00556.x

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  33 in total

Review 1.  Nucleoside transporters: from scavengers to novel therapeutic targets.

Authors:  Anne E King; Michael A Ackley; Carol E Cass; James D Young; Stephen A Baldwin
Journal:  Trends Pharmacol Sci       Date:  2006-07-03       Impact factor: 14.819

2.  Depletion of major vault protein increases doxorubicin sensitivity and nuclear accumulation and disrupts its sequestration in lysosomes.

Authors:  Mikael Herlevsen; Gary Oxford; Charles R Owens; Mark Conaway; Dan Theodorescu
Journal:  Mol Cancer Ther       Date:  2007-06       Impact factor: 6.261

Review 3.  Review article: thiopurines in inflammatory bowel disease.

Authors:  L J J Derijks; L P L Gilissen; P M Hooymans; D W Hommes
Journal:  Aliment Pharmacol Ther       Date:  2006-09-01       Impact factor: 8.171

4.  6-Mercaptopurine decreases the Bcl-2/Bax ratio and induces apoptosis in activated splenic B lymphocytes.

Authors:  S Hortelano; L Boscá
Journal:  Mol Pharmacol       Date:  1997-03       Impact factor: 4.436

5.  Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.

Authors:  J Wijnholds; C A Mol; L van Deemter; M de Haas; G L Scheffer; F Baas; J H Beijnen; R J Scheper; S Hatse; E De Clercq; J Balzarini; P Borst
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

6.  Anticancer nucleobase analogues 6-mercaptopurine and 6-thioguanine are novel substrates for equilibrative nucleoside transporter 2.

Authors:  Katsuhito Nagai; Kazuki Nagasawa; Yukiko Kihara; Hiroto Okuda; Sadaki Fujimoto
Journal:  Int J Pharm       Date:  2006-09-29       Impact factor: 5.875

7.  The broadly selective human Na+/nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics.

Authors:  Kyla M Smith; Melissa D Slugoski; Shaun K Loewen; Amy M L Ng; Sylvia Y M Yao; Xing-Zhen Chen; Edward Karpinski; Carol E Cass; Stephen A Baldwin; James D Young
Journal:  J Biol Chem       Date:  2005-05-03       Impact factor: 5.157

Review 8.  The equilibrative nucleoside transporter family, SLC29.

Authors:  Stephen A Baldwin; Paul R Beal; Sylvia Y M Yao; Anne E King; Carol E Cass; James D Young
Journal:  Pflugers Arch       Date:  2003-06-28       Impact factor: 3.657

9.  Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines.

Authors:  Alan Kambiz Fotoohi; Malin Lindqvist; Curt Peterson; Freidoun Albertioni
Journal:  Biochem Biophys Res Commun       Date:  2006-03-03       Impact factor: 3.575

Review 10.  Physiology of nucleoside transporters: back to the future. . . .

Authors:  Jennifer B Rose; Imogen R Coe
Journal:  Physiology (Bethesda)       Date:  2008-02
View more
  3 in total

1.  Expression of Wnt and Notch signaling pathways in inflammatory bowel disease treated with mesenchymal stem cell transplantation: evaluation in a rat model.

Authors:  Yanfen Xing; Xiaojie Chen; Yanwen Cao; Jianyun Huang; Xuhong Xie; Yaming Wei
Journal:  Stem Cell Res Ther       Date:  2015-05-22       Impact factor: 6.832

Review 2.  How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion.

Authors:  Douglas B Kell; Stephen G Oliver
Journal:  Front Pharmacol       Date:  2014-10-31       Impact factor: 5.810

Review 3.  Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.

Authors:  Mauro Cataldi; Chiara Vigliotti; Teresa Mosca; MariaRosaria Cammarota; Domenico Capone
Journal:  Int J Mol Sci       Date:  2017-06-10       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.